Tr1X, pronounced "Trix", develops cell therapies to treat autoimmune and inflammatory diseases. Tr1X's therapies are based on regulatory T cell-based therapeutics that mimic the function of Type 1 regulatory T (Tr1) cells. Tr1X's cells work similarly to natural Tr1 cells by: (1) Homing to inflammation sites (2) Suppressing unwanted activity (3) Increasing the production of antigen-specific Tr1 cells (4) Resetting the immune system and restoring balance. Tr1X's technology is designed to convert donor-derived T cells into Treg-like cells. Treg-like cells have a similar function and profile to natural Tr1 cells.

<p>Tr1X, pronounced &quot;Trix&quot;, develops cell therapies to treat autoimmune and inflammatory diseases. Tr1X&#39;s therapies are based on regulatory T cell-based therapeutics that mimic the function of Type 1 regulatory T (Tr1) cells. Tr1X&#39;s cells work similarly to natural Tr1 cells by: (1) Homing to inflammation sites (2) Suppressing unwanted activity (3) Increasing the production of antigen-specific Tr1 cells (4) Resetting the immune system and restoring balance.</p>
<p>Tr1X&#39;s technology is designed to convert donor-derived T cells into Treg-like cells. Treg-like cells have a similar function and profile to natural Tr1 cells.</p>


Tr1X

Senior Clinical Trial Manager

Senior Clinical Research Associate

Scientist I, Translational Sciences

Sr. Scientist, Bioanalytical Sciences

Senior Medical Director, Immunology

 VC roundup: Tr1X, Disco among the week's launches 

Tr1x, a new biotech, joins ‘Treg’ chase with $75M fundraise - BioPharma Dive

Tr1X, Inc. Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T (Treg) and CAR-Treg Cell Therapies to Treat and Potentially Cure Autoimmune and Inflammatory Diseases - PR Newswire

 Tr1X, Inc. Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T (Treg ... 

Tr1X - BioSpace

 Tr1X Gets $75M In Series A 

Our Team

TRX-103 cleared for clinic in treatment-refractory Crohn’s disease - BioWorld Online

 Tr1x's TRX-103 to enter phase I following IND clearance 

Open source re-implementation of Tomb Raider 1 (1996) TR1X gets a big bug-fix release - GamingOnLinux

Tr1X doses first patient in trial of TRX103 for GvHD prevention - Clinical Trials Arena


              Tr1X to Participate at Upcoming Healthcare Investment Conferences
            

 Tr1x’s TRX-103 to enter phase I following IND clearance 

www.tr1x.bio

Tr1X Secures $75M Series A - San Diego Business Journal

Tomb Raider 1 open source engine TR1X adds a 60FPS mode - GamingOnLinux

Tr1X has received FDA clearance for our IND application for TRX103, the first ever #allogeneic engineered Tr1 regulatory T cell therapy in the clinic. We are now focused delivering proof-of-concept data in Graft versus Host Disease (GvHD), while continuing our pipeline work for multiple autoimmune and inflammatory diseases with high unmet need. #Innovation #Biotech #CellTherapy #clinicaltrial

Read more here: https://lnkd.in/gC6VtiSi

 Tr1X Biotech Innovates In Autoimmune Therapy With $75M Fundraise 

Tr1X is proud to announce our $75 Million Series A Financing, led by The Column Group with participation from NEVA SGR & Alexandria Real Estate Equities, Inc.. This funding will propel us toward our goal of bringing universal allogeneic regulatory T (Treg) and CAR-Treg cell therapies to the clinic to treat and potentially cure autoimmune and inflammatory diseases. 

Discover more in our press release: https://lnkd.in/gTMJsmjz
 
And stay connected with us to receive regular updates along our journey.
 
#Biotech #SeriesAFinancing #AutoimmuneDisease #CellTherapy

Open source re-implementation of Tomb Raider 1 'TR1X' gets Linux builds - GamingOnLinux


              Frontiers | From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases
            

Read the release here

 The Week’s 10 Biggest Funding Rounds: Quantinuum And Flexport Lock Up Huge Rounds 

 Cell Therapy Startup Tr1X Emerges from Stealth with $75M Series A 

Neva Sgr invests in Tr1X, leading biotech company in researching cures for autoimmune and inflammatory diseases - Intesa Sanpaolo

 Tr1x, a new biotech, joins 'Treg' chase with $75M fundraise 

Tr1X Announces First Patient Dosed in Proof of Concept GvHD - GlobeNewswire

 Tr1X Announces FDA Clearance of First Investigational New Drug Application for TRX103, an Allogeneic Regulatory T ... 

Tr1X Announces FDA Clearance of First Investigational New Drug Application for TRX103, an Allogeneic Regulatory T-Cell Therapy to Treat Autoimmune Diseases - PR Newswire

 Tr1X Announces First Patient Dosed in Proof of Concept GvHD 

Neva Sgr invests in US biotech firm Tr1X - Intesa Sanpaolo

 Tr1X Raises $75M in Series A Funding 


              Graphite Bio co-founder debuts Treg cell therapy startup with $75M, aims to ‘trick’ immune system into resetting
            

 Cell Therapy Startup With Stanford Roots Unveils $75M to Seek Inflammation Cures 

Tr1X Announces FDA Clearance of IND Application for TRX103, - GlobeNewswire

Graphite Bio co-founder debuts Treg cell therapy startup with $75M, aims to ‘trick’ immune system into resetting - Endpoints News

Tr1X to Participate at Upcoming Healthcare Investment Conferences - GlobeNewswire

Tr1X Bio


              Tr1X Announces First Patient Dosed in Proof of Concept GvHD Trial Evaluating TRX103, a First-in-Class Type 1 Treg (Tr1) Cell Therapy
            

 Tr1X Secures $75M Series A 

TR1X: How to play Tomb Raider 1 on GNU/Linux without Steam? - Desde Linux

Investors@tr1x.bio

We are happy to share we have received U.S. FDA IND clearance for 
#TRX103 in the treatment of patients with refractory Crohn's Disease. This represents the second IND Clearance for our #allogeneic #Tr1 #Treg cell therapy. We look forward to sharing more  updates throughout the rest of the year as we tackle this devastating #autoimmune and #inflammatory disease. Read more here: https://lnkd.in/gvDyPEEv

Maria Grazia Roncarolo Marco Londei Muhi Davis Viktoriya Megrabova James Adams Ryan Bjordahl Yu Alex Kato Daryl Humes Matthew Breton Lyndsey Young Jie Wei Leon Chen Liliana Nordbakk John T. Dimos, PhD Mario Costantini Sarah Hymowitz

Cell Therapy Startup Tr1X Emerges from Stealth with $75M Series A - BioSpace


              Planning for success with an allogeneic Treg cell sourcing strategy
            


              Lab Meeting: Maria Grazia Roncarolo
            

Tr1X

Business:

Drug notes:

About: